Next Article in Journal
Intestinal Microbiotas and Alcoholic Hepatitis: Pathogenesis and Therapeutic Value
Next Article in Special Issue
Personalized Assessment for Cancer Prevention, Detection, and Treatment
Previous Article in Journal
The IFIH1/MDA5 rs1990760 Gene Variant (946Thr) Differentiates Early- vs. Late-Onset Skin Disease and Increases the Risk of Arthritis in a Spanish Cohort of Psoriasis
Previous Article in Special Issue
Investigation of Mutated in Colorectal Cancer (MCC) Gene Family Evolution History Indicates a Putative Role in Th17/Treg Differentiation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 19
10.3390/ijms241914807
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Human T-Cell Leukemia Virus Type 1 Oncogenesis between Active Expression and Latency: A Possible Source for the Development of Therapeutic Targets

by
Francesca Marino-Merlo
1,†,
Sandro Grelli
2,†,
Antonio Mastino
3,
Michele Lai
4,
Paola Ferrari
5,
Andrea Nicolini
6,*,
Mauro Pistello
4,‡ and
Beatrice Macchi
7,‡
1
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy
2
Department of Experimental Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy
3
The Institute of Translational Pharmacology, CNR, 00133 Rome, Italy
4
Retrovirus Center and Virology Section, Department of Translational Research, University of Pisa, 56100 Pisa, Italy
5
Unit of Oncology, Department of Medical and Oncological Area, Azienda Ospedaliera—Universitaria Pisana, 56125 Pisa, Italy
6
Department of Oncology, Transplantations and New Technologies in Medicine, University of Pisa, 56126 Pisa, Italy
7
Department of Chemical Science and Technology, University of Rome “Tor Vergata”, 00133 Rome, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
‡
These authors contributed equally to this work.
Int. J. Mol. Sci. 2023, 24(19), 14807; https://doi.org/10.3390/ijms241914807
Submission received: 13 August 2023 / Revised: 16 September 2023 / Accepted: 28 September 2023 / Published: 30 September 2023
(This article belongs to the Special Issue Cancer Prevention with Molecular Target Therapies 4.0)
Browse Figures
Review Reports Versions Notes

Abstract

The human T-cell leukemia virus type 1 (HTLV-1) is the only known human oncogenic retrovirus. HTLV-1 can cause a type of cancer called adult T-cell leukemia/lymphoma (ATL). The virus is transmitted through the body fluids of infected individuals, primarily breast milk, blood, and semen. At least 5–10 million people in the world are infected with HTLV-1. In addition to ATL, HTLV-1 infection can also cause HTLV-I-associated myelopathy (HAM/TSP). ATL is characterized by a low viral expression and poor prognosis. The oncogenic mechanism triggered by HTLV-1 is extremely complex and the molecular pathways are not fully understood. However, viral regulatory proteins Tax and HTLV-1 bZIP factor (HBZ) have been shown to play key roles in the transformation of HTLV-1-infected T cells. Moreover, several studies have shown that the final fate of HTLV-1-infected transformed Tcell clones is the result of a complex interplay of HTLV-1 oncogenic protein expression with cellular transcription factors that subvert the cell cycle and disrupt regulated cell death, thereby exerting their transforming effects. This review provides updated information on the mechanisms underlying the transforming action of HTLV-1 and highlights potential therapeutic targets to combat ATL.
Keywords: HTLV-1; adult T-cell leukemia; viral oncogenesis; Tax; HBZ; apoptosis HTLV-1; adult T-cell leukemia; viral oncogenesis; Tax; HBZ; apoptosis

Share and Cite

MDPI and ACS Style

Marino-Merlo, F.; Grelli, S.; Mastino, A.; Lai, M.; Ferrari, P.; Nicolini, A.; Pistello, M.; Macchi, B. Human T-Cell Leukemia Virus Type 1 Oncogenesis between Active Expression and Latency: A Possible Source for the Development of Therapeutic Targets. Int. J. Mol. Sci. 2023, 24, 14807. https://doi.org/10.3390/ijms241914807

AMA Style

Marino-Merlo F, Grelli S, Mastino A, Lai M, Ferrari P, Nicolini A, Pistello M, Macchi B. Human T-Cell Leukemia Virus Type 1 Oncogenesis between Active Expression and Latency: A Possible Source for the Development of Therapeutic Targets. International Journal of Molecular Sciences. 2023; 24(19):14807. https://doi.org/10.3390/ijms241914807

Chicago/Turabian Style

Marino-Merlo, Francesca, Sandro Grelli, Antonio Mastino, Michele Lai, Paola Ferrari, Andrea Nicolini, Mauro Pistello, and Beatrice Macchi. 2023. "Human T-Cell Leukemia Virus Type 1 Oncogenesis between Active Expression and Latency: A Possible Source for the Development of Therapeutic Targets" International Journal of Molecular Sciences 24, no. 19: 14807. https://doi.org/10.3390/ijms241914807

APA Style

Marino-Merlo, F., Grelli, S., Mastino, A., Lai, M., Ferrari, P., Nicolini, A., Pistello, M., & Macchi, B. (2023). Human T-Cell Leukemia Virus Type 1 Oncogenesis between Active Expression and Latency: A Possible Source for the Development of Therapeutic Targets. International Journal of Molecular Sciences, 24(19), 14807. https://doi.org/10.3390/ijms241914807

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop